Company: LGNZZ
Filing Date: 2025-05-09
Form Type: 10-Q
Source: 0000886163-25-000036
Chunk: 5

Company: LIGAND PHARMACEUTICALS INC
Filing Date: 2025-05-09
Form: 10-Q
Item: Item 1
Chunk 5
---
 (expense)7,729 (27,308)Net (loss) income $(42,451)$86,139      Basic net (loss) income per share$(2.21)$4.86      Shares used in basic per share calculation19,191 17,732      Diluted net (loss) income per share$(2.21)$4.75      Shares used in diluted per share calculation19,191 18,122 

See accompanying notes to unaudited condensed consolidated financial statements.

5

LIGAND PHARMACEUTICALS INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME 

(Unaudited)

(in thousands)

Three months endedMarch 31,20252024Net (loss) income$(42,451)$86,139 Unrealized net loss on available-for-sale securities, net of tax(22)(93)Foreign currency translation adjustment, net of tax4,401 — Comprehensive (loss) income $(38,072)$86,046 

See accompanying notes to unaudited condensed consolidated financial statements.

6

LIGAND PHARMACEUTICALS INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY 

(Unaudited)

(in thousands)

Common StockAdditional paid in capitalAccumulated other comprehensive lossRetained earningsTotal stockholders' equitySharesAmountBalance at December 31, 202419,106 $20 $337,377 $(5,942)$498,984 $830,439 Issuance of common stock under employee stock compensation plans, net of shares withheld for payroll taxes170 — (4,669)— — (4,669)Share-based compensation— — 7,836 — — 7,836 Unrealized loss on available-for-sale securities, net of tax— — — (22)— (22)Foreign currency translation adjustment, net of tax— — — 4,401 — 4,401 Net loss— — — — (42,451)(42,451)Balance at March 31, 202519,276 $20 $340,544 $(1,563)$456,533 $795,534 

Common StockAdditional paid in capitalAccumulated other comprehensive income (loss)